Five-Year Data Confirm Benefit of Jakafi in Myelofibrosis

Final five-year efficacy and safety data of the JAK-2 inhibitor, Jakafi, confirmed previous findings of the treatment's benefit for patients with myelofibrosis.  
BY LAURA PANJWANI
PUBLISHED: JUNE 20, 2016
The JAK-2 inhibitor Jakafi (ruxolitinib) has a significant benefit for patients with with intermediate-2 and high-risk myelofibrosis, according to final five-year efficacy and safety data from the phase 3 COMFORT-I trial. The treatment resulted in durable reductions in splenomegaly and improved overall survival, with patients experiencing no new or unexpected adverse events as a result of the long-term treatment. These data were presented at the 2016 European Hematology Association (EHA) Congress, a gathering of thousands of hematology and oncology professionals from around the world.

Among patients originally randomized to Jakafi, 59 percent had at least a 35 percent reduction in spleen volume at any time on study, which was the study’s primary endpoint. The median duration of response was 168 weeks.

Overall survival (OS) at a median follow-up of 268.4 weeks was not reached in the Jakafi randomized arm and was 200 weeks in the placebo arm.

These long-term findings reaffirm the primary endpoint and support longer term use of the drug, said Ruben A. Mesa, investigator on COMFORT-I and chair, Hematology, at the Mayo Clinic in Arizona, who reported the results at the 2016 European Hematology Association Congress. “We are able to see that there is a clear survival advantage for patients with Jakafi compared to the control arm.”

COMFORT-I randomized patients aged 18 years or older with intermediate-2 or high-risk myelofibrosis and splenomegaly to a twice-daily regimen of either Jakafi (155 patients) or placebo (154 patients). Patients with a platelet (PLT) count of 100-200 × 109/L received a 15 mg dose of the study drug, and those whose PLT count was more than 200 × 109/L received 20 mg. Crossover to Jakafi was permitted before week 24 for patients experiencing protocol-defined increasing splenomegaly and following the primary analysis. The preplanned five-year analysis occurred when all patients reached the five-year visit or discontinued therapy.
 
The median time to crossover in the placebo arm was 41 weeks, and a large number of patients (111 patients) crossed over. “It is noteworthy that the control arm was initially on placebo, but by 81 weeks everyone had crossed over to Jakafi,” said Mesa. “The trial really became Jakafi versus delayed Jakafi, and still we see a strong survival advantage.”
 
Reductions in spleen volume were shown to be rapid and durable in both the Jakafi -randomized and the crossover arms in the long-term follow-up.
 
All patients completed week 24, and more than 50 percent completed week 36 of treatment. This is particularly exciting, said Mesa, as the life expectancy of the patients enrolled in this study was around three years or less on average.
 
“This demonstrates a significant survival benefit,” he said.
 
Treatment-Emergent Adverse Events Remain Steady

Toxicities between the primary and follow-up analyses were consistent with the well-characterized safety profile of Jakafi, said Mesa. “We are able to reaffirm that there were no unexpected long-term toxicities, even up through five years,” he said.
 


Talk about this article with other patients, caregivers, and advocates in the Myelodysplastic syndrome CURE discussion group.
x-button
Special Feature
Share Your Art
Related Articles
Making Progress for Myelodysplastic Syndrome
In an interview with CURE, Rami Komrokji, M.D., a hematologist at Moffitt Cancer Center in Tampa, Florida, discusses the advances that have been made in MDS in the past few years, as well as the MDS Clinical Research Consortium and its importance.
The Roller Coaster of MDS
MDS is a rare form of cancer with its own unique characteristics. Here is one patients perspective on the experience of having MDS.
The Wonder of the Oncology Nurse
What do oncology nurses mean to their patients? This is an inside view from one grateful patient.
Related Videos
Filling an Unmet Need in MDS Treatment
Rami S. Komrokji, M.D., clinical director of Hematologic Malignancies at Moffitt Cancer Center, discusses an unmet need in the treatment of myelodysplastic syndrome (MDS).
Barbara Van Husen on Improvements in MPN Research
Barbara Van Husen, president of the MPN Research Foundation, discusses how after the discovery of the JAK2 mutation in 2005, MPN research and treatment advances proliferated. Now, Van Husen says, it is one of the most active areas of hematological research
Jennifer Arnold on the Importance of Listening
Jennifer Arnold, our MPN Heroes guest speaker, a physician and star of TLC’s reality TV show “The Little Couple,” discusses the importance of doctors and caregivers taking a moment to listen to patients and see how they are feeling. 
x
//For side ad protocol